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Introduction
Exposure to tobacco smoke is a significant public health issue 
as there are approximately 4700 chemicals present in tobacco 
smoke of which 250 are known to be toxic or carcinogenic [1]. 
Most notably, tobacco smoke has nicotine, tar, nitric oxide, 
carbon monoxide, aromatic amines [2], formaldehyde, benzene, 
hydrogen cyanide, acetone, and Polonium-210 [3]. Although the 
prevalence of smoking cigarettes has decreased since the release 
of the U.S. Surgeon General's Report on Smoking and Health in 
1966, there remains approximately 13.4% of the U.S. population 
who smoke daily and 5.4% who smoke some days [4]. Smoking 
is associated with approximately 480,000 deaths annually in the 
U.S., including 42,000 deaths from secondhand smoke (SHS) 
exposure [5]. The cost of smoking in the U.S. is $300 billion per 
year ($170 billion in medical care, $156 billion in lost productivity 
due to premature death) [5]. Even limited or light smoking 
has health risks. Tobacco usage has been associated with lung 
diseases, cancers, cardiovascular disease, stroke, mood disorders, 
rheumatoid arthritis, headache, and fibromyalgia among other 
diseases and conditions [6,7]. Smoking also has the potential to 
be a risk factor for chronic pain [6,7].
The conceptual framework of chronic pain is that it is a situation 
in which a person has an ongoing negative subjective experience 
with many biopsychosocial factors and interactions (any of which 
may have clinical significance) [8]. Researchers have varying 
definitions of the cut-point at which pain is defined as chronic. 
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Purpose: Tobacco smoke exposure continues to be the leading preventable risk 
factor for many diseases and has the potential to be a risk factor for chronic pain. 
The purpose of this study is to determine the relationship of chronic pain with 
smoking, secondhand smoke exposure and non-smoking using serum cotinine 
(and self-report of living with someone who smokes in the home) to identify the 
tobacco exposure groups.
Methods: The National Health and Nutrition Examination Survey (NHANES) 2003-
2004 was used for this study. Participants were queried about pain duration 
and had serum cotinine levels determined during the course of the NHANES 
examination/survey. Participants, ages 20 years and above, with complete data on 
chronic pain, cotinine level, sex, race/ethnicity, and responses concerning living 
with someone who smoked in the home were included in the study (n=4429).
Results: The adjusted odds ratio of tobacco smoke exposure on chronic pain was 
1.67 (95% CI: 1.08, 2.59; p=0.0220) for participants with a serum cotinine level >10 
ng/mg (smokers) as compared with individuals who had a non-detectable serum 
cotinine level. For individuals with a serum cotinine level >0.011 ng/mg to 10 ng/
mg who identified as living with someone who smoked in the home, the adjusted 
odds ratio was 0.88 (95% CI: 0.47, 1.65; p=0.6785) as compared with individuals 
who had a non-detectable serum cotinine level.
Conclusion: Chronic pain is a complex situation with many factors affecting 
it. Similarly, smoking is a complex addiction. The interplay of chronic pain and 
cotinine levels in this study were significant.
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Typical cut-points are 3 months, 6 months, and 12 months pain 
duration. In a recent U.S. study, the prevalence of chronic pain, 
defined as lasting at least 6 months, was 30.7% [9]. Researchers 
using 2008 Medical Expenditure Panel Survey data estimated 
100 million adults in the U.S. had chronic pain and the total costs 
were from $560 to $635 billion in 2010 dollars [10].
The purpose of this study is to determine the relationship 
of chronic pain with smoking, SHS exposure, tobacco smoke 
exposure of unknown source, and non-smoking using serum 
cotinine (and self-report of living with or not living with someone 
who smokes in the home) to identify the tobacco exposure 
groups. The theoretical framework is the biopsychosocial model 
of health as explained by Ditre, et al. [6] in which, for smoking and 
chronic pain, there is an interplay or positive feedback loop with 
greater pain, increased smoking, and maintenance of the tobacco 
addiction through biomedical, behavioral, cognitive/affective, and 
physiological/sensory phenomena in social context. The research 
hypothesis is that smoking is more strongly associated with 
chronic pain than non-smoking as measured by serum cotinine 
level.
Methods
Participants
Data from the National Health and Nutrition Examination Survey 
(NHANES) 2003-2004 was used for this study. Researchers from 
the Centers for Disease Control and Prevention conduct surveys 
of non-institutionalized U.S. civilians using a multistage, stratified 
probability design. The study design is representative of the U.S. 
population. All participants provide verbal and written consent. 
Details of the sampling strategy are available from the NHANES 
website: http://www.cdc.gov/nchs/nhanes.htm.
This study is a cross-sectional, secondary data analysis of the 
publicly available, de-identified NHANES 2003-2004 data. The 
sample for the study of chronic pain and smoking was limited to 
participants who had no missing data concerning chronic pain, 
cotinine level, sex, age, race/ethnicity, and responses concerning 
living with someone who smoked in the home. Participants were 
also limited to the ages of 20 years and above as the NHANES 
questions concerning pain were presented to participants who 
were at least age 20 years. The final sample size was 4429 
participants.
Outcome variable: Chronic pain
Chronic pain was the outcome variable. It was derived from 2 
NHANES questions. The first question asked of participants was 
if they had pain that lasted more than 24 hours in the previous 
month. The second question asked of participants who endorsed 
the first question, was the length of time that the pain was 
experienced. Options for the second question were: less than a 
month; one to less than 3 months; 3 months to less than a year; 
and greater than a year. For this study, pain lasting at least 3 
months was defined as chronic pain, based on the definition of 
the American College of Rheumatology and previous research 
[11,12].
Key independent variable: Tobacco smoke exposure 
(Serum cotinine levels)
Serum cotinine level was the key independent variable. Based 
upon previous definitions using serum cotinine levels [2,13], 
a participant was defined as a smoker if he or she had a serum 
cotinine level above10 ng/mg. A participant was defined as 
having SHS exposure if he or she self-identified as living in a home 
in which someone smoked and had a cotinine level greater than 
0.011 ng/mg but less than or equal to 10 ng/mg. A participant was 
defined as having tobacco smoke exposure of unknown source if 
he or she indicated he or she did not live in a home in which 
someone smoked and had a cotinine level greater than 0.011 
ng/mg but less than or equal to 10 ng/mg. Individuals with non-
detectable serum cotinine levels were defined as non-smokers.
Other important variables
Variables considered in the study were selected to address the 
biopsychosocial theoretical framework: age (20 years to less than 
45 years, 45 years to less than 60 years, and 60 years and above); 
sex (male, and female); race/ethnicity (Non-Hispanic white, Non-
Hispanic black, Mexican American, and other); income to poverty 
ratio (less than 1.25, 1.25 to less than 2.00, 2.00 to less than 4.00, 
and 4.00 and above); education (less than High School, High 
School graduate, more than High School); marital status (married 
and not married); body mass index (less than 25, 25 to less than 
30, 30 and above); insurance (yes and no); exercise (yes and no); 
and alcohol use (heavy, moderate, and none). Heavy alcohol use 
was defined as an average of more than 2 drinks a day on the 
days in which the participant drank, and moderate alcohol use 
was defined as an average of 1 or 2 drinks a day on the days in 
which the participant drank.
Statistical analysis
The data were analyzed with SAS 9.3® (Cary, NC). Variable 
frequencies were determined for the characteristics of the 
study participants. Bivariate associations of the serum cotinine 
levels and other important variables with chronic pain were 
conducted with Chi square analyses. Significant variables in the 
bivariate analyses were included in the logistic regression model 
development for the association of serum cotinine levels on 
chronic pain. Due to the complex study design of the NHANES 
data, considerations were made for the selected eligible sample, 
masked variance pseudo-stratum (SDMVSTRA), masked variance 
pseudo-primary sampling unit (SDMVPSU) and full sample 2 
year Mobile Examination Center exam weight (WTMEC2YR) in 
the bivariate analyses and logistic regressions. The alpha for the 
analysis was established, a priori, as 0.05.
Results
The sample had 17.9% (n=733) of participants reporting chronic 
pain and 29.6% (n=1172) of participants having serum cotinine 
levels >10 ng/mg. There were 51.6% (n=2284) females; 49.6% 
(n=1916) ages 20-45 years, and 55.1% (n=2022) who had more 
than a high school education. Most of the participants were non-
Hispanic white (72.5%; n=2369); insured (82.2%; n=3576); and 
married (64.4%; n=2688). Details of the study characteristics are 
presented in Table 1.
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N=Number; SE=Standard Error; NHW=Non-Hispanic White; NHB=Non-Hispanic Black; Am=American
SHS=Second Hand Smoke Exposure
1tobacco smoke exposure of unknown source
N Weighted Frequency Weighted column % (SE)             
Sample 4429
Chronic Pain >= 3 mo
Yes  733 34,646,810 17.9 (1.3)
No 3701 159,247,675 82.1 (1.3)
Serum Cotinine
>10 ng/mg (Smoker)           1172 57,424,400 29.6 (1.7)
>0.011 to 10 ng/mg (SHS)     202 9,072,581 4.7 (0.5)
>.011 to 10 ng/mg1 2213 96,018,432 49.5 (1.4)
Non-detectable 837 31,379,072 16.2 (2.0)
Sex  
Male   2145 93,889,884 48.4 (0.7)
Female   2284 100,004,601 51.6 (0.7)
Age groups in years
20 to less than 45 1916 96,183,603 49.6 (1.6)
45 to less than 60               882 5,378,911 27.7 (1.3)
60 and above 1631 43,929,971 22.7 (1.0)
Race/ethnicity
NHW 2369 16,267,413 72.5 (3.3)
NHB  847 20,925,464 10.8 (1.7)
Mexican Am                          887 14,925,350 7.7 (2.0)
Other 326 17,411,975 9.0 (1.0)
Family income to poverty ratio
0 to less than 1.25     1144 34,797,004 18.8 (1.6)
1.25 to less than 2.00          786 27,762,464 15.0 (0.7)
2.00 to less than 4.00 1185 57,514,789 31.1 (1.3)
4.00 and above  1104 64,793,554 35.0 (2.1)
Insurance
Yes                                        3576 159,272,926 82.2 (0.9)
 No                                          851 34,474,920 17.8 (0.9)
Education
Less than high school 1290 35,006,250 18.1 (0.7)
High school graduate       1111 51,972,076 26.8 (1.1)
More than high school 2022 106,793,926 55.1 (1.3)
Marital Status
Married     2688 124,734,732 64.4 (1.3)
Not married 1739 68,891,444 35.6 (1.3)
Body mass index
Less than 25 1361 63,457,655 33.2 (1.0)
25 to less than 30  1553 66,318,721 34.7 (1.1)
30 and above 1429 61,149,655 32.0 (1.2)
Exercise
Yes 2267 112,186,435 57.8 (1.1)
No 2161 81,678,646 42.1 (1.1)
Alcohol
Heavy use 942 46,058,168 28.4 (1.7)
Moderate use 1360 65,900,422 40.6 (1.8)
Non-drinker 1274 50,225,392 31.0 (2.2)
Table 1 Sample characteristics, NHANES 2003-04.
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Chronic Pain  N Yes Weighted row % N No Weighted row % p-value
Serum Cotinine <.0001
>10 ng/mg (Smoker) 252 23.9 920 76.1
>0.011 ng/mg (SHS) 35 16.4 172 83.5
>0.011 ng/mg to 0 ng/mg1 324 15.0 1889 85.0
Non-detectable 117 16.0 720 84.0
Sex       0.0317
Male 304 15.4 1841 84.6
Female                             424 20.2 1860 79.8
Age groups in years
20 to less than 45 260 14.4 1656 85.6
45 to less than 60 185 22.7 697 77.3
 60 and above   283   19.6 1348 80.4
Race/ethnicity    <0.0001
NHW 466 19.9 1903 80.1
NHB 117 14.1 730 85.9
Mexican Am 97 9.5 790 90.5
Other                                        48 13.5 278    86.5
Family income to poverty ratio 0.0039   
0 to less than 1.25 222 22.0 922 78.0
1.25 to less than 2.00 129 18.8 657 81.2
2.00 to less than 4.00          196 19.7 989 80.3
4.00 and above 150 14.0 954 86.0
Insurance  0.1995
Yes 594 18.2 2982 81.8
 No  133 16.3 718 83.7
Education
Less than high school 220 19.8 1070 80.2
High school graduate  197 20.6 914 79.4
More than high school 311 15.9 1711 84.1
Marital Status 0.3966
married 442 18.4 2264 81.6
not married 286 16.9 1453 83.1
Body mass index 0.2599
Less than 25 207 16.6 1154 83.4
25 to less than 30  237 17.6 1316 82.4
30 and above     268 19.5 1161 80.5
Exercise   <0.0001
Yes 332 15.5 1935 84.4
No 396 21.1 1765 78.9
Alcohol 0.7986
Heavy use 137 16.4 805 83.6
Moderate use 209 17.1 1151 82.9
Non-drinker 220 18.0 1054 82.0
N=Number; NHW= Non-Hispanic White; NHB= Non-Hispanic Black; Am=American
SHS=Secondhand Smoke Exposure 
1tobacco smoke exposure of unknown source
Table 2 Bivariate relationship of chronic pain with variables of interest, NHANES 2003-04. 
The results of the bivariate relationships with chronic pain are 
presented in Table 2. The key variable, tobacco smoke exposure 
(serum cotinine level), was significantly associated with chronic 
pain (p<0.0001). Other significant variables were sex, age, race/
ethnicity, family income to poverty ratio, education, and exercise. 
Marital status, body mass index, and alcohol use failed to reach 
significance.
The logistic regression models are presented in Table 3. The 
unadjusted odds ratio of tobacco smoke exposure (serum cotinine 
level) on chronic pain was 1.65 (95% CI: 1.18, 2.30; p=0.0032) for 
participants with a serum cotinine level >10 ng/mg (smokers) 
as compared with individuals who had a non-detectable serum 
cotinine level. For individuals with a serum cotinine level greater 
thand.011 ng/mg but less than or equal to 10 ng/mg who 
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Unadjusted Odds Ratios (95%CI) 2001-2002 p-value
Serum Cotinine level
>10 ng/mg (Smoker)   1.65 (1.18, 2.30) 0.0032
>0.011 ng/mg to 10 ng/mg (SHS 1.04 (0.63, 1.69) 0.8910
>0.011 ng/mg to 10 ng/mg1 0.93 (0.71, 1.23) 0.6226
Non-detectable         reference
Adjusted Odds Ratios (95% CI)
Serum Cotinine level
>10 ng/mg (Smoker)  1.67 (1.08, 2.59) 0.0220
>0.011 ng/mg to 10 ng/mg (SHS)   0.88 (0.47, 1.65 0.6785
>0.011 ng/mg to 10 ng/mg1 1.01 (0.70, 1.46) 0.9624
Non-detectable reference
Sex 0.0463
Male 0.73 (0.53, 1.00)
Female reference group
Age groups
20 to less than 45 reference group
45 to less than 60 1.71 (1.31, 2.24) 0.0001
60 and above 1.35 (0.98, 1.85) 0.0639
Race/ethnicity
NHB 1.86 (1.38, 2.50) <0.0001
Mexican Am 1.52 (1.06, 2.17) 0.9216
Other 0.65 (0.39, 1.07) 0.0886
NHW reference group
Family income to poverty
0 to <1.25 1.86 (1.38, 2.50) <0.0001
1.25 to <2.00 1.52 (1.06, 2.17) 0.9216
2.00 to <4.00 1.50 (1.02, 2.20) 0.0399
4.00 and above reference group
Education
Less than High School 1.20 (0.93, 1.56) 0.1706
High School Graduate 1.16 (0.89, 1.51) 0.2701
More than High School reference group
Exercise
No 1.34 (1.08, 1.66) 0.0075
Yes reference group
Abbreviations: CI: Confidence Interval; <- less than; NHB: Non-Hispanic Black; NHW: Non-Hispanic White; Am: American; SHS: Second Hand Smoke 
Exposure.  
1tobacco smoke exposure of unknown source 
Table 3 Logistic regression on chronic pain, NHANES 2003-04 by Serum Cotinine level.
identified as living with someone who smoked in the home, the 
unadjusted odds ratio was 1.04 (95% CI: 0.63, 1.69; p=0.8910) 
as compared with individuals who had a non-detectable serum 
cotinine level. For individuals who reported that they did not live 
with someone who smoked in the home and who had a serum 
cotinine level greater than .011ng/mg but less than or equal to 
10 ng/mg, the unadjusted odds ratio was 0.93 (95% CI: 0.71, 
1.23; p=0.6226) as compared with individuals who had a non-
detectable serum cotinine level.
The adjusted odds ratio of tobacco smoke exposure (serum 
cotinine level) on chronic pain was 1.67 (95% CI: 1.08, 2.59; 
p=0.0220) for participants with a serum cotinine level >10 ng/
mg (smokers) as compared with individuals who had a non-
detectable serum cotinine level. For individuals with a serum 
cotinine level greater than.011 ng/mg but less than or equal to 
10 ng/mg who identified as living with someone who smoked 
in the home, the adjusted odds ratio was 0.88 (95% CI: 0.47, 
1.65; p=0.6785) as compared with individuals who had a non-
detectable serum cotinine level. For individuals who reported 
that they did not live with someone who smoked in the home 
and who had a serum cotinine level greater than.011 ng/mg but 
less than or equal to 10 ng/mg, the adjusted odds ratio was 1.01 
(95% CI: 0.70, 1.46; p=0.9624) as compared with individuals who 
had a non-detectable serum cotinine level.
Discussion
Research associated with nationally representative data 
concerning chronic pain is limited.  The purpose of this study was 
to determine the relationship of chronic pain with smoking, SHS 
exposure and non-smoking using serum cotinine (and self-report 
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of living with someone who smokes in the home) to identify 
the tobacco exposure groups. There were 17.9% of participants 
endorsing having chronic pain lasting 3 or more months. There 
were 29.6% of participants having serum cotinine levels greater 
than 10 ng/mg. The adjusted odds ratio for smokers as compared 
with non-smokers on chronic pain was 1.65 (95% CI: 1.18, 2.30; 
p=0.0032). Results did not reach significance for individuals with 
cotinine levels greater than.011 ng/mg but less than or equal to 
10 ng/mg for chronic pain as compared with non-smokers. This 
study adds to the literature results indicating smoking, as defined 
with cotinine levels, is a risk factor for chronic pain.
Other studies
• Similar results for the association of chronic pain and 
tobacco smoke exposure were reported concerning a 
rural population in which current smoking was associated 
with chronic musculoskeletal pain (odds ratio 1.60; 95% 
CI: 1.04, 2.46) and chronic back pain (odds ratio 1.58; 95% 
CI: 1.13, 2.20) [13].
• In a U.S. nationally representative study, researchers 
found self-reported chronic pain and nicotine dependence 
(diagnosed using the World Health Organization 
Composite International Diagnostic Interview for trained 
non-clinicians) to be associated. Participants who 
endorsed current chronic neck or back pain were 2.30 
(95% CI: 1.71, 3.11) times more likely to have current 
nicotine dependence than participants without current 
chronic neck or back pain [14]. 
•  In a large, representative sample in Canada in which 
participants were asked about current cigarette use and 
pain lasting 6 months or longer, participants who had 
chronic back pain or arthritis were 1.54 (95% CI: 1.44, 
1.65) times more likely to be daily cigarette smokers [15]. 
The results were adjusted for sociodemographic variables, 
mood disorders, and anxiety [15]. 
•  In a large survey conducted in Britain, smokers had higher 
risk for regional pain lasting 24 hours or more in the past 
12 months than non-smokers (prevalence ratio 1.3, 95% 
CI: 1.2, 1.4 for low back pain) [15,16].
Biological plausibility
From the late 1970’s, there was research on the effect of smoking 
on pain in which nicotine was shown to release endogenous 
opiates that relieve pain; additionally, dysphoric states such as 
pain were also determined to be cues to smoke by providing the 
situation (discriminative stimulus) for smoking reinforcement with 
beta-endorphin release [17]. Much of the research involved acute 
pain (cold water, pressure, etc.) [17]. Nicotine activates nicotinic 
acetylcholine receptors (nAChRs) throughout the central nervous 
system to release dopamine, noradrenaline, acetylcholine, 
glutamate and GABA [18]. Endogenous enkephalins and beta-
endorphins have roles in the rewarding effects of nicotine [18]. It 
is therefore biologically plausible that chronic pain is temporarily 
relieved by smoking, and the addiction cycle is strengthened in a 
feedback loop.
Strengths and limitations
The study does have limitations. It is a cross-sectional study, and by 
nature does not imply causality or temporality. Misclassification 
of people exposed to SHS was possible since the definition was 
dependent upon correct self-report of living with someone 
who smoked. Misclassification is also possible in that the blood 
sample may have been taken on a day in which a smoker had 
not smoked for several days. (The half-life of plasma cotinine is 
15-20 hours) [19]. Additionally, the cut-point for cotinine is not 
firmly established in the literature.  Researchers from Britain 
have suggested a cut-point of 12ng/ml as an overall cut-point for 
salivary cotinine levels [20]. 
A study strength is the use of the large representative NHANES 
sample which was publicly available from the CDC. The data 
collection, verification and representative study design of the 
original NHANES 2003-2004 also are strengths for this study. 
Additionally, cotinine, a biomarker for tobacco smoke exposure, 
was used to identify smokers. Its use has the potential to correctly 
identify individuals who smoke avoiding the social desirability 
bias that may be associated with a self-report. The large national 
nature of the study increases its potential for generalizability.
Conclusion 
Chronic pain is a complex situation with many factors affecting it. 
Similarly smoking is a complex addiction. The interplay of chronic 
pain and smoking were significant in this study. Additional 
research is needed to understand the relationship more fully.   
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